AATB accreditation: what it covers and how to vet a tissue supplier
The AATB was founded in 1976 by the doctors and scientists who had started the United States Navy Tissue Bank in 1949. It publishes the Standards for Tissue Banking (first issued in 1984), certifies tissue bank staff through the Certified Tissue Bank Specialist (CTBS) credential, and since 1986 has run the only private accreditation program for tissue banks in the United States. Since 1 January 2026 the association has operated as the Association for Advancing Tissue and Biologics, a 501(c)(6) trade association, and the historic American Association of Tissue Banks became the AATB Foundation. Many supplier certificates and web pages still carry the former name; AATB gave accredited establishments until 31 December 2026 to update their own documents.
Accreditation is scoped by tissue and by activity
An AATB accreditation is not a blanket approval. After an application, an on-site inspection by independent assessors and a review by the AATB Accreditation Committee, the association issues a certificate and letter that name the specific functions and tissue products covered. Accreditation is valid for three years, and new applicants must already have operated in full compliance with the Standards for at least six months, with records for every activity performed in that period.
| Dimension | Categories AATB uses for accredited establishments |
|---|---|
| Tissue | Musculoskeletal, Skin, Birth Tissue, Cardiac, Vascular, Reproductive, Autologous Tissue, Cellular, Surgical Bone |
| Activity | Acquisition, collection or recovery; authorization or informed consent; donor screening; donor eligibility assessment and determination; preparation or processing; storage; distribution or dispensing |
The practical consequence for a buyer: a bank accredited to process musculoskeletal tissue may hold no accreditation for skin or birth tissue, and a donor network accredited for recovery and donor screening may not process or distribute grafts at all. Match the scope on the certificate to the graft you are buying and to the role the supplier plays in the chain from donor to hospital.
AATB accreditation, FDA registration and state licences are separate checks
- FDA registration is mandatory. Under 21 CFR Part 1271, an establishment that manufactures human cells, tissues, and cellular and tissue-based products (HCT/Ps) must register and list its HCT/Ps within 5 days of beginning operations and update its registration every December. Registration is per establishment, so a processor with several plants holds several registrations.
- AATB accreditation is voluntary. Not every tissue bank holds it; accredited banks are inspected again on a three-year cycle.
- State licences and registrations are issued separately. Supplier certification pages commonly list licences or registrations from New York, California, Florida, Maryland, Oregon, Illinois, Delaware and Louisiana, sometimes one per site.
- International registrations such as Health Canada's cells, tissues and organs (CTO) registration or an entry on Australia's Register of Therapeutic Goods matter when tissue crosses borders.
A vetting checklist for value-analysis and supply-chain teams
- Confirm the supplier appears in AATB's Accredited Establishment Search and that its certificate is within the three-year term.
- Check that the accredited tissue categories and activities cover the product: processing, storage and distribution for a finished allograft, not only recovery.
- Confirm the FDA HCT/P registration of each site that handles the product; FDA-CBER publishes a public query of registered human cell and tissue establishments.
- Confirm the licence or registration your state requires, plus Health Canada or other registrations for cross-border supply.
- Where a product is also regulated as a medical device, ask for the device registration and an ISO 13485 certificate as well; several accredited processors hold both.
Who holds AATB accreditation
AATB counts over 120 accredited tissue establishments around the world. They include non-profit tissue banks and organ and tissue donor networks that recover tissue and screen donors; processors that turn donated tissue into bone, tendon, ligament, dermal and amniotic allografts; and companies focused on birth tissue, cardiovascular grafts, cells or reproductive tissue. Most are in the United States, with others in Canada, Europe and Asia. Some processors, such as LifeLink Tissue Bank, openly seek partners for contract processing of musculoskeletal or birth tissue.
Reimbursement is also shifting demand. AATB reports that the 2026 Medicare Physician Fee Schedule from CMS sets outpatient payment for skin substitutes at $127.28 per cm² regardless of whether the product is a PMA device, a 510(k) device or a 361 HCT/P, which matters to birth-tissue and dermal allograft suppliers serving wound care.